Prognostic significance of T-lineage leukemic cell growth in SCID mice: a Children's Cancer Group study.

Contemporary intensive therapies are effective for the majority of pediatric T-lineage acute lymphoblastic leukemia (ALL) patients, thus current challenge is to identify patients who may benefit from alternative treatment modalities. Previously, we demonstrated that human leukemic cell growth in the severe combined immunodeficiency (SCID) mouse was a significant prognostic factor for very high risk B-lineage ALL patients. In the current report we show that primary leukemic cells from 24 of 88 (27%) T-lineage ALL patients (SCID+) caused histopathologically detectable leukemia in SCID mice. These SCID+ patients were similar to SCID- (n = 64) patients with respect to virtually all presenting features, including age, sex, race, and leukocyte count. Growth of primary leukemic cells in SCID mice was not a significant predictor of outcome for the aggregate population of T-lineage ALL patients. Two-year event-free survival (EFS) outcomes for SCID+ patient and SCID- patients were 76.2% (SD = 5.6%) and a 64.0% (SD = 10.4%; p = 0.20). Overall survival also was similar between the two groups (p = 0.36). Among the subset of patients with M1 or M2 marrow status by day 7 of induction chemotherapy (rapid early responders), those who were SCID+ had poorer outcomes than those who were SCID-, with a 2-year EFS of 68.4% (SD = 11.9%) vs. 85.7% (SD = 6.0%) and relative hazard rate of 3.06 (p = 0.06). These data suggest that leukemic cell growth in SCID mice may identify a subset of T-lineage ALL patients who are at higher risk for relapse despite achieving a rapid early response to induction chemotherapy.

[1]  W. Evans,et al.  In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  H. Sather,et al.  Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Sather,et al.  Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Sather,et al.  CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study , 1996 .

[5]  H. Sather,et al.  Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. , 1996, Leukemia & lymphoma.

[6]  F. Uckun.  Severe combined immunodeficient mouse models of human leukemia. , 1996, Blood.

[7]  H. Sather,et al.  Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Tumer,et al.  In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells. , 1995, Blood.

[9]  C. Pui,et al.  Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. , 1995, Blood.

[10]  J. Jin,et al.  In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. , 1995, Blood.

[11]  A. Bleyer,et al.  Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. , 1995, Blood.

[12]  W. Hiddemann,et al.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. , 1994, Blood.

[13]  J. Downing,et al.  Human t(4;11)(q21;q23) acute lymphoblastic leukemia in mice with severe combined immunodeficiency. , 1994, Blood.

[14]  J. Harbott,et al.  Konzeption und Zwischenergebnis der Therapiestudie ALL-BFM 90 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: Die Bedeutung des initialen Therapieansprechens in Blut und Knochenmark , 1994 .

[15]  R. Gelber,et al.  Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Pituch-Noworolska,et al.  [Treatment results of T-cell acute lymphoblastic leukemia therapy in children from 1983-1985]. , 1994, Polski tygodnik lekarski.

[17]  F. Behm,et al.  Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. , 1993, Blood.

[18]  J. Downing,et al.  Human t(1;19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency. , 1993, Blood.

[19]  J. Irvin,et al.  In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. , 1993, Leukemia.

[20]  Dorothea,et al.  Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. , 1992, Blood.

[21]  J. Shuster,et al.  Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study. , 1992, Leukemia.

[22]  D. Arthur,et al.  In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. , 1992, Blood.

[23]  S. Kamel‐Reid,et al.  Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice. , 1991, Blood.

[24]  J. Dick,et al.  Transplantation of Normal and Leukemic Human Bone Marrow into Immune‐Deficient Mice: Development of Animal Models for Human Hematopoiesis , 1991, Immunological reviews.

[25]  Denis R. Miller,et al.  Lymphomatous presentation of childhood acute lymphoblastic leukemia. A subgroup at high risk of early treatment failure , 1991, Cancer.

[26]  B. Lange,et al.  Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice. , 1991, Blood.

[27]  B. Haynes,et al.  Successful engraftment of human postnatal thymus in severe combined immune deficient (SCID) mice: differential engraftment of thymic components with irradiation versus anti-asialo GM-1 immunosuppressive regimens , 1991, The Journal of experimental medicine.

[28]  A. Bernard,et al.  Comparison of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL. The Groupe d'Etude Immunologique des Leucémies. , 1990, Leukemia.

[29]  J. Dick,et al.  A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. , 1989, Science.

[30]  J. Shuster,et al.  Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group Study. , 1988, Blood.

[31]  J. Ledbetter,et al.  Immunobiologic differences between normal and leukemic human B-cell precursors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Sather,et al.  INTENSIVE THERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND UNFAVOURABLE PRESENTING FEATURES Early Conclusions of Study CCG-106 by the Childrens Cancer Study Group , 1988, The Lancet.

[33]  I. Weissman,et al.  The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. , 1988, Science.

[34]  Donald E. Mosier,et al.  Transfer of a functional human immune system to mice with severe combined immunodeficiency , 1988, Nature.

[35]  M. Borowitz,et al.  Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen‐positive childhood T‐cell leukemia A pediatric oncology group study , 1987, Cancer.

[36]  J. Ritter,et al.  Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) , 1987 .

[37]  R. Gelber,et al.  Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.

[38]  A. Bleyer,et al.  Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Cooper,et al.  Pediatric Oncology Group Utilization of Immunologic Markers in the Designation of Acute Lymphocytic Leukemia Subgroups: Influence on Treatment Response a , 1984, Annals of the New York Academy of Sciences.

[40]  K. Starling,et al.  Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study). , 1982, Blood.

[41]  J. Peto,et al.  Immunologically Defined Subclasses of Acute Lymphoblastic Leukaemia in Children: their Relationship to Presentation Features and Prognosis , 1981, British journal of haematology.

[42]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[43]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[44]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[45]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  H. Sather,et al.  Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. , 1990, Medical and pediatric oncology.

[47]  Jonathan J. Shuster,et al.  Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study , 1990 .

[48]  F. Behm,et al.  Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. , 1990, Blood.

[49]  F. Uckun,et al.  Immunophenotype-karyotype associations in human acute lymphoblastic leukemia. , 1989, Blood.

[50]  J. Pullen,et al.  Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: a Pediatric Oncology Group review. , 1986, Medical and pediatric oncology.

[51]  G. Henze,et al.  Thymic involvement and initial white blood count in childhood acute lymphoblastic leukemia. , 1981, The American journal of pediatric hematology/oncology.